Aldeyra Therapeutics Inc (ALDX)

2.40 +0.16  +7.14% NASDAQ Apr 9, 10:30 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
05/08/2020 08:00 EDT Misc Aldeyra Therapeutics Inc First Quarter Earnings Conference Call in 2020
05/08/2020 Earnings Aldeyra Therapeutics Inc First Quarter Earnings in 2020 Release
03/12/2020 08:00 EDT Misc Aldeyra Therapeutics Inc Fourth Quarter Earnings Conference Call for 2019
03/12/2020 Earnings Aldeyra Therapeutics Inc Fourth Quarter Earnings in 2019 Release
03/12/2020 Misc Aldeyra Therapeutics Inc Annual Report for 2019
11/07/2019 08:00 EST Misc Aldeyra Therapeutics Inc Third Quarter Earnings Conference Call for 2019
11/07/2019 Earnings Aldeyra Therapeutics Inc Third Quarter Earnings Results for 2019
08/09/2019 08:00 EDT Misc Aldeyra Therapeutics Inc Second Quarter Earnings Conference Call in 2019
08/09/2019 Earnings Aldeyra Therapeutics Inc Second Quarter Earnings in 2019 Release
06/04/2019 08:00 EDT Misc Aldeyra Therapeutics Inc Annual General Meeting in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.aldeyra.com
  • Investor Relations URL: http://ir.aldeyra.com/
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: May. 08, 2020
  • Last Earnings Release: Mar. 12, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye diseases, allergic conjunctivities, noninfectious anterior uveitis, and Sjogren-Larsson Syndrome. The company is also developing other product candidates for proliferative vitreoretinopathy and other retinal disease, post-transplant lymphoproloferative disease, autoimmune disease, metabolic disease, and cancer. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.